Kidney Ischemia and Reperfusion Injury – Field of Glory or Warterloo for Erythropoietin?
Journal Title: Nephrology – Open Journal - Year 2016, Vol 1, Issue 3
Abstract
When asking clinicians about their knowledge about Erythropoietin (EPO) most of them would say that it increases Red Blood Cell (RBC) count and can therefore be used to treat anemia, is produced in the kidneys and can be misused as doping agent in sports. The way to reach this today’s common knowledge was long and hard. In the year 1667 by giving a lambs blood to an anemic patient and the lucky outcome that the patient felt better afterwards, it became clear that blood could heal.1 Over two centuries later in a rabbit experimental set-up where plasma was transduced between an anemic and a healthy animal it could be seen that the red blood cell count increased in the anemic one. This gave birth to the thesis that a humeral factor is responsible and was named hemopoietin.2 Seventy years later this mysterious substance was found by Goldwasser in patients´ urine3 and was later on cloned by a colleague of him4 what marked the beginning of EPOs therapeutic career in treating anemia that lasts on until today.
Authors and Affiliations
Florian Simon
Continuous Renal Replacement Therapy for Acute Kidney Injury Using Phosphate Containing Fluid is Associated With Greater Biochemical Derangement than Conventional Fluid
Background: Continuous Renal Replacement Therapy (CRRT) is the preferred means of renal replacement therapy (RRT) in many intensive care units. Most units use only one type of RRT fluid or identify a standard ‘default’ f...
Current Trends in Chronic Kidney Disease
Chronic kidney disease (CKD), a major contributor to health care burden, is defined by persistent indicators of renal structural and or functional abnormalities. Diabetes mellitus, hypertension, and obesity are important...
Androgen and Androgen Receptor in Kidney Cancer
Kidney cancer is one of the top ten most common cancers in men and women. There are four types of kidney cancer, including Renal Cell Carcinoma (RCC), Transitional cell carcinoma, renal sarcoma, and Wilm’s tumor. The mos...
Pediatric Genitourinary Tumors-Clinicopathological Experience
Objective: To document general baseline data on the patterns of childhood genitourinary tumors. Design, Setting and Participants: This is a retrospective analysis of 28 cases of pediatric genitourinary tumors (Age group...
Fibroblast Growth Factor 23 as a Therapeutic Target
This fibroblast growth factor-23 (FGF-23) has been found as a circulating hormone and pathogenic factor in many disease conditions. This review focuses on recent advances in FGF-23 as a therapeutic target, including fibr...